Contribution of somatostatin analogues to the implementation of a patient-oriented approach to the treatment of acromegaly

Acromegaly is a severe disabling disease, the management of which usually requires a multidis-ciplinary treatment approach and lifelong use of medications. The success of long-term drug therapy depends on the effectiveness and safety of the drugs used. The review presents data on modern forms of drug treatment of acromegaly and the mechanisms of action of somatostatin analogues of the 1st generation (SA1) in acromegaly. A comparative analysis of clinical studies concerning the effectiveness and tolerability of prolonged forms of octreotide and lanreotide as primary or secondary drug therapy was performed. Data on patient adherence to long-term SA1 therapy in terms of efficacy, safety, and tolerability of pharmacological drugs are presented. A new form of release of lanreotide Autogel is presented, created with the active participation of patients and medical personnel themselves, and has obvious advantages over injectable forms of octreotide-containing drugs. The most rational schemes of combined treatment in the presence of resistance to SA1 are described, depending on the receptor phenotype and the severity of metabolic disorders. According to clinical studies, there was a great commitment of patients to the use of lanreotide Autogel both as monotherapy and in combination with other drugs.

acromegaly, pituitary adenoma, drug therapy, somatostatin analogues, lanreotide Autogel